CIK 0001811063 · Non-accelerated filer<br>Smaller reporting company
Nuvation Bio Inc.
Sign in to watch- Ticker
- NUVB
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 850862255
- Phone
- 332-208-6102
- Business address
- 1 PENNSYLVANIA PLAZA, SUITE 3805, NEW YORK, NY, 10019
- Former names
- Panacea Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $709,240
- in 1 filing, $709K under 10b5-1 plans
Net −$709,240. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-21 | Bazemore Robert B Director | Grant or award · Stock Option (Right to Buy) | +123,397 | 123,397 | ||
| 2026-05-21 | Cui Xiangmin Director | Grant or award · Stock Option (Right to Buy) | +123,397 | 123,397 | ||
| 2026-05-21 | VERNON W ANTHONY Director | Grant or award · Stock Option (Right to Buy) | +123,397 | 123,397 | ||
| 2026-05-21 | BLICKENSTAFF KIM D Director | Grant or award · Stock Option (Right to Buy) | +123,397 | 123,397 | ||
| 2026-05-21 | FALBERG KATHRYN E Director | Grant or award · Stock Option (Right to Buy) | +123,397 | 123,397 | ||
| 2026-04-17 | Liu Dongfang CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +50,000 | $1.94 | $97K | 68,000 |
| 2026-04-17 | Liu Dongfang CHIEF MEDICAL OFFICER | Sale 10b5-1 | −50,000 | $5.02 | $251K | 18,000 |
| 2026-04-17 | Liu Dongfang CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −50,000 | 430,000 | ||
| 2026-04-17 | Wentworth Kerry CHIEF REGULATORY OFFICER | Option exercise 10b5-1 | +36,750 | $2.93 | $108K | 89,750 |
| 2026-04-17 | Wentworth Kerry CHIEF REGULATORY OFFICER | Sale 10b5-1 | −36,750 | $5.01 | $184K | 53,000 |
| 2026-04-17 | Wentworth Kerry CHIEF REGULATORY OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −36,750 | 215,250 | ||
| 2026-04-06 | Wentworth Kerry CHIEF REGULATORY OFFICER | Option exercise 10b5-1 | +100,000 | $1.87 | $187K | 153,000 |
| 2026-04-06 | Wentworth Kerry CHIEF REGULATORY OFFICER | Option exercise 10b5-1 | +100,000 | $1.94 | $194K | 253,000 |
| 2026-04-06 | Wentworth Kerry CHIEF REGULATORY OFFICER | Sale 10b5-1 | −200,000 | $4.52 | $904K | 53,000 |
| 2026-04-06 | Wentworth Kerry CHIEF REGULATORY OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100,000 | 400,000 | ||
| 2026-04-06 | Wentworth Kerry CHIEF REGULATORY OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100,000 | 300,000 | ||
| 2026-02-27 | Cui Xiangmin Director | Grant or award · Stock Option (Right to Buy) | +76,923 | 76,923 | ||
| 2026-02-27 | Sauvage Philippe Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +748,130 | 748,130 | ||
| 2026-02-27 | Sjogren Colleen Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +748,130 | 748,130 | ||
| 2026-02-27 | Makunje Moses SEE REMARKS | Grant or award | +50,761 | 68,137 |
Page 2 of 15 · 291 trades